We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hemoglobin Assay Based on Fluorescent Quenching Technology

By HospiMedica staff writers
Posted on 23 Nov 2006
A new assay for glycated hemoglobin (A1C) is based on fluorescent quenching technology. More...
The amount of glucose that combines with the hemoglobin is directly proportional to the total amount of glucose that is currently in an individual's system. The assay will aid in the diagnosis of diabetes and subsequent follow-up of patients.

The A1C level provides an overall record of glucose levels for as long as the individual red blood cells live, which is about two or three months. Whereas the fasting glucose test gives an indication of current glucose levels, the A1C gives a picture of average levels over the whole two-to-three-month period.

The fluorescence of a conjugate of boronic acid and a fluorophore is reduced (or "quenched”) upon binding to cis-diol groups that are present on carbohydrates attached to hemoglobin molecules. Utilizing solid state opto-electronic technology, a desktop reader quantifies the concentration of A1C in the sample. The total amount of hemoglobin is then quantified by absorption measurement. The combination of these two values produces an A1C % result.

Called Quo-Test, the fully automated homogenous assay system was developed by Quotient Diagnostics (Surrey, UK). There are no separation steps, and the system controls all the critical steps that may influence or affect the quality of the result. Results are delivered in about three minutes from a blood sample of less than 5 µl. The starter kit contains a reader, barcode scanner, mini-printer, and a pack of 10 disposable cartridges.

Diabetes is one of the most challenging health problems in the 21st century, with close to 200 million people worldwide already diagnosed as having the disease. In addition, there is strong reason to believe that more than half of the diabetics in the world remain undiagnosed. According to Quotient's CEO David Chatterton, the trend is for both diagnosis and follow-up to be performed in special clinics, hence the development of Quo-Test. "We have drawn on our broad experience in both assay and instrument development to create an instrument that we are confident will have a major impact on diabetes care,” he explained.




Related Links:
Quotient Diagnostics

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.